Repeat: Treatment.com AI Provides an Update on the Status of Exercised Warrants

Rhea-AI Summary

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.

CEO Dr. Essam Hamza highlighted that this cash injection will help expedite the company's plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI has also mentioned a strong acquisition pipeline under review, which could accelerate their growth strategy.

Positive

• Nearly 800,000 warrants exercised, raising approximately $500,000
• Remaining warrants could potentially bring in over $2 million
• Plans to launch 'AI Patient' and 'AI Doctor in the Pocket' products in fall 2024
• Strong acquisition pipeline under review for potential growth acceleration

Negative

• None.

●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.

●Remaining warrants could bring over $2 million in additional funds.

●Robust acquisition pipeline

VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024.

Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars.

Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our “AI Patient” and “AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another $2 Million injection to the treasury.”

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >92%+ accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. The platform’s quality and transparency are unrivaled, as the GLM provides an explanation of every step and likelihood associated with every symptom. Treatment.com AI also focuses on the next generation of healthcare professionals supporting Medical and Nursing schools, who utilize the GLM to help enhance the future clinical skills of their students. Treatment.com AI is focused on using AI for good and utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities.

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

ehamza@treatment.com

If you would like to find out more about Treatment’s products and services, please email at info@treatment.com

For media inquiries, contact: media@treatment.com

Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955

Cautionary Statements

This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

FAQ

How many warrants were exercised for Treatment.com AI (TREIF) in July 2024?

Nearly 800,000 warrants were exercised for Treatment.com AI (TREIF) in July 2024, raising gross proceeds of approximately half a million dollars.

What is the potential additional funding from remaining warrants for Treatment.com AI (TREIF)?

The remaining warrants for Treatment.com AI (TREIF) could potentially bring in over $2 million in additional funds.

What new products is Treatment.com AI (TREIF) planning to launch in fall 2024?

Treatment.com AI (TREIF) is planning to launch 'AI Patient' and 'AI Doctor in the Pocket' products in fall 2024.

What is Treatment.com AI's (TREIF) strategy for growth acceleration?

Treatment.com AI (TREIF) has a strong acquisition pipeline under review, which could potentially accelerate their growth strategy.